Advertisement

Pharmaceutisch Weekblad

, Volume 13, Issue 1, pp 32–38 | Cite as

Investigating drug use in pregnancy

Methodological problems and perspectives
  • L. T. W. De Jong-van den Berg
  • P. B. Van den Berg
  • F. M. Haaijer-Ruskamp
  • M. N. G. Dukes
  • H. Wesseling
Articles

Abstract

In this study the use of prescribed drugs before, during and after pregnancy is described. The study is based on data obtained from pharmacy records of 1,948 women who delivered a live-born infant. Different measures to evaluate drug exposure are used. During the nine months of pregnancy 86% of the women used on average 4.2 prescriptions. During the course of pregnancy the use of gastro-intestinal and blood-forming drugs increased, whereas the use of cardiovascular, antiphlogistic and central nervous system drugs decreased. Anti-emetics were predominantly used in the first trimester, and antacids in the last trimester, whereas laxatives were especially used after delivery. The percentage of women who used a treatment for vaginal infections increased from 2 to 7 during pregnancy. Most of the women (73%) received one or more iron prescriptions during the course of pregnancy, however, the prescribed daily dose was low (prescribed daily dose/defined daily dose=0.6). At least 1% of the women filled a new prescription for anticonceptives in the first trimester of pregnancy. Most likely, our data reflect the general prescribing pattern for Dutch pregnant women who delivered a live-born baby. Therefore, they form a good and detailed base for further studies, for instance, on the exposure to drugs with known or suspected risks or on the use of drugs in patients with chronic concomitant diseases. Such studies may lead to recommendations that may improve prescribing behaviour.

Keywords

Drug utilization Epidemiological methods Lactation Pregnancy Prenatal care 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Anonymous. Drugs in pregnancy and delivery. Report on the 13th European Symposium on clinical pharmacological evaluation in drug control. Geneva: World Health Organization, 1984.Google Scholar
  2. 2.
    Koren G, Bologa M, Long D, Feldman Y, Shear NH. Perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimester. Am J Obstet Gynecol 1989;160:190–4.Google Scholar
  3. 3.
    Brocklebank JC, Ray WA, Federspiel ChF, Schaffner W. Drug prescribing during pregnancy: a controlled study of Tenessee Medicaid recipients. Am J Obstet Gynecol 1978;132:235–44.Google Scholar
  4. 4.
    Bodendorfer TW, Briggs GG, Gunning JE. Obtaining drug exposure histories during pregnancy. Am J Obstet Gynecol 1979;135:490–4.Google Scholar
  5. 5.
    Piper JM, Baum C, Kennedy DL. Prescription drug use before and during pregnancy in a Medicaid population. Am J Obstet Gynecol 1987;157:148–57.Google Scholar
  6. 6.
    Hill RM. Drugs ingested by pregnant women. Clin Pharmacol Ther 1973;14:632–42.Google Scholar
  7. 7.
    Rubin PC, Craig CF, Gavin K, Sumner D. Prospective study of therapeutic drugs, alcohol and cigarettes during pregnancy. Br Med J 1986;292:81–3.Google Scholar
  8. 8.
    Forfar JO, Nelson MM. Epidemiology of drugs taken by pregnant women: drugs that may affect the fetus adversely. Clin Pharmacol Ther 1973;14:632–42.Google Scholar
  9. 9.
    Eskes TKAB, Nijdam WS. Epidemiology of drug intake during pregnancy. In: Eskes TKAB, Finster M, eds. Drugs and pregnancy. London: Academic Press, 1984:17–84.Google Scholar
  10. 10.
    Collaborative Group on Drug Use in Pregnancy. Drug use in pregnancy: a preliminary report of the International Co-operative Drug Utilization Study. Pharm Weekbl [Sci] 1990;12:75–8.Google Scholar
  11. 11.
    Kullander S, Kallen B. A prospective study of drugs and pregnancy. Acta Obstet Gynecol Scand 1976;35:25–35.Google Scholar
  12. 12.
    Mitchell AA, Cottler LB, Shapiro S. Effect of questionnaire design on recall of drug exposure in pregnancy. Am J Epidemiol 1986;123:670–6.Google Scholar
  13. 13.
    Harlow S, Linet MS. Agreement between questionnaire data and medical records: the evidence for accuracy of recall. Am J Epidemiol 1989;129:233–48.Google Scholar
  14. 14.
    Haaijer-Ruskamp FM. Drug utilization studies in the Netherlands. Pharm Weekbl [Sci] 1990;12:91–6.Google Scholar
  15. 15.
    Nordic Council on Medicines. Nordic statistics on Medicines 1984–1986. Uppsala: Nordic Drug Index with Classification and Defined Daily Doses, 1988.Google Scholar
  16. 16.
    De Smet PAGM, Leufkens HGM. ATC-classificaties en DDD-waarden [ATC classifications and DDD values]. In: De Smet PAGM, Van Loenen AC, Van der Does E, eds. Informatorium Medicamentorum III. Alphen a/d Rijn: Samsom Stafleu, 1987:300–32.Google Scholar
  17. 17.
    De Smet PAGM. The Dutch approach to computerized drug information: conceptual basis and realization. Soc Adm Pharm 1988;5:49–58.Google Scholar
  18. 18.
    Anonymous. Do all pregnant women need iron? Br Med J 1978;2:13–7.Google Scholar
  19. 19.
    Needs CJ, Brooks PM. Antirheumatic medication in pregnancy. Br J Rheumatol 1985;24:282–90.Google Scholar
  20. 20.
    Anonymous. Vademecum gezondheidsstatistiek Nederland [Manual health statistics in the Netherlands]. Voorburg: Centraal Bureau voor de Statistiek, 1989: 72–84.Google Scholar
  21. 21.
    Daalen R. Dutch obstetric care: home or hospital, midwife or gynaecologist? Health Promotion 1988;2:247–55.Google Scholar
  22. 22.
    Evans L, Spelman M. The problem of non-compliance with drug therapy. Drugs 1983;25:63–76.Google Scholar
  23. 23.
    De Jong-van den Berg LTW, Van den Berg PB, Peters PWJ, Haaijer-Ruskamp FM. A study of drug utilization during pregnancy in the light of known risks: is there room for improvement? Int J Risk Safety 1990;1:91–105.Google Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1991

Authors and Affiliations

  • L. T. W. De Jong-van den Berg
    • 1
  • P. B. Van den Berg
    • 1
  • F. M. Haaijer-Ruskamp
    • 2
  • M. N. G. Dukes
    • 2
  • H. Wesseling
    • 3
  1. 1.Department of Pharmacology and Pharmacotherapeutics, Section Pharmacy and SocietyUniversity Centre for PharmacyAW GroningenThe Netherlands
  2. 2.Department of Health SciencesUniversity of GroningenAV GroningenThe Netherlands
  3. 3.Department of Pharmacology/Clinical PharmacologyUniversity Centre for PharmacyGroningen

Personalised recommendations